These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 32007639)

  • 1. Goal-Oriented Monitoring of Cyclosporine Is Effective for Graft-versus-Host Disease Prevention after Hematopoietic Stem Cell Transplantation in Sickle Cell Disease and Thalassemia Major.
    Gauthier A; Bleyzac N; Garnier N; Kebaili K; Joly P; Goutagny MP; Mollet I; Goutelle S; Renard C; Bertrand Y
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2285-2291. PubMed ID: 32007639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
    Zaidman I; Rowe JM; Khalil A; Ben-Arush M; Elhasid R
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1043-1048. PubMed ID: 27016193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
    Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
    JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.
    Kharbanda S; Smith AR; Hutchinson SK; McKenna DH; Ball JB; Lamb LS; Agarwal R; Weinberg KI; Wagner JE
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):581-6. PubMed ID: 24370862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
    Soni S; Gross TG; Rangarajan H; Baker KS; Sturm M; Rhodes M
    Pediatr Blood Cancer; 2014 Sep; 61(9):1685-9. PubMed ID: 24740582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
    Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of allogeneic Hematopoietic Stem Cell Transplantation on Diamond-Blackfan anemia using busulfan-based myeloablative regimen.
    Behfar M; Koochakzadeh L; Yazdanian N; Salajegheh P; Rostami T; Khodayari-Namini N; Ghavamzadeh A; Hamidieh AA
    Turk J Pediatr; 2019; 61(3):407-412. PubMed ID: 31916719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors.
    Martin P; Bleyzac N; Souillet G; Galambrun C; Bertrand Y; Maire PH; Jelliffe RW; Aulagner G
    Bone Marrow Transplant; 2003 Oct; 32(8):777-84. PubMed ID: 14520421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical study on haploid HLA-matched hematopoietic stem cell transplantation for treatment of malignant hematological disease].
    Sun AN; Wu DP; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Fu ZZ; Ma X; Han Y; He GS; Chen SN; Xue SL; Zhao Y
    Ai Zheng; 2006 Aug; 25(8):1019-22. PubMed ID: 16965686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa.
    Khandelwal P; Yeh RF; Yu L; Lane A; Dandoy CE; El-Bietar J; Davies SM; Grimley MS
    Transplantation; 2021 Apr; 105(4):891-896. PubMed ID: 32467478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of tacrolimus vs. cyclosporine in pediatric hematopoietic stem cell transplantation for thalassemia.
    Zhumatayev S; Yalcin K; Celen SS; Karaman I; Daloglu H; Ozturkmen S; Uygun V; Karasu G; Yesilipek A
    Pediatr Transplant; 2024 Feb; 28(1):e14688. PubMed ID: 38317344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matched Family versus Alternative Donor Hematopoietic Stem Cell Transplantation for Patients with Thalassemia Major: Experience from a Tertiary Referral Center in South India.
    Swaminathan VV; Uppuluri R; Patel S; Ravichandran N; Ramanan KM; Vaidhyanathan L; Ramakrishnan B; Jayakumar I; Raj R
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1326-1331. PubMed ID: 32200123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic/Matched Related Transplantation for β-Thalassemia and Sickle Cell Anemia.
    Bernaudin F; Pondarré C; Galambrun C; Thuret I
    Adv Exp Med Biol; 2017; 1013():89-122. PubMed ID: 29127678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretransplant myeloid and immune suppression, reduced toxicity conditioning with posttransplant cyclophosphamide: Initial outcomes of novel approach for matched unrelated donor hematopoietic stem cell transplant for hemoglobinopathies.
    Kharya G; Bakane AN; Rauthan AM
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28909. PubMed ID: 33470527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-Agent Cyclosporine for Graft-versus-Host Disease Prophylaxis in Patients with Acquired Aplastic Anemia Receiving Fludarabine-Based Conditioning.
    Iftikhar R; Chaudhry QUN; Mahmood SK; Ghafoor T; Satti HS; Shahbaz N; Khan MA; Khattak TA; Shamshad GU; Rehman J; Farhan M; Humayun S; Risalat A; Wahab A; Satti TM; Anwer F; Ahmed P
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2245-2251. PubMed ID: 32717437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease.
    Locatelli F; Rocha V; Reed W; Bernaudin F; Ertem M; Grafakos S; Brichard B; Li X; Nagler A; Giorgiani G; Haut PR; Brochstein JA; Nugent DJ; Blatt J; Woodard P; Kurtzberg J; Rubin CM; Miniero R; Lutz P; Raja T; Roberts I; Will AM; Yaniv I; Vermylen C; Tannoia N; Garnier F; Ionescu I; Walters MC; Lubin BH; Gluckman E;
    Blood; 2003 Mar; 101(6):2137-43. PubMed ID: 12424197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.